The filing signals an officer's intent to sell a relatively small portion of holdings. Given the modest size relative to market cap and the insider's routine option exercise, this is unlikely to indicate a material change in company outlook. Monitor for actual sale execution on Form 4.
REGN drugs
REGN drug pipeline →- ● Otarmeni 3/10 Approved (accelerated approval) · BLA filing 2026
- ▲ Cemdisiran 6/10 Filed/PDUFA (Phase 3 NIMBLE complete; NDA under FDA Priority Review)
- ▲ Dupixent 4/10 Approved (marketed since 2017; additional Phase 3 trials ongoing for label expansion)
- ● Evkeeza 4/10 Approved
- ● EYLEA HD 4/10 Approved
- 12 more · All REGN drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 3 $973.36entry
- T+1 · 13d ago −4.39%α −6.04% · $930.67
- T+5 · 7d ago −5.89%α −5.30% · $916.06
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Joseph LaRosa, an officer of Regeneron Pharmaceuticals, filed a Form 144 notice of intent to sell 4,466 shares of common stock with an approximate market value of $4.3 million, based on a filing date of November 2, 2026. The shares were acquired via stock option exercise on January 3, 2024, and the sale is planned for execution on or after November 2, 2026.
Key Facts
- Joseph LaRosa (Officer) filed Form 144 to sell 4,466 shares of Regeneron common stock.
- Estimated market value of proposed sale: $4,311,875.12.
- Shares were acquired via stock option exercise on January 3, 2024.
- Proposed sale date: November 2, 2026.
- Broker: UBS Financial Services Inc.
- Regeneron market cap: $84.3 billion; proposed sale represents ~0.005% of market cap.
Financial Impact
Proposed sale of $4.3 million in shares, representing approximately 0.005% of Regeneron's $84.3 billion market cap.
Risk Factors
- Form 144 is an intent to sell; the sale may not be executed.
- Insider selling could be perceived negatively if followed by additional filings from other officers.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001969223-26-001114 |
| Document: 0001969223-26-001114-index.html | 0001969223-26-001114 |
| Document: 0001969223-26-001114.txt | 0001969223-26-001114 |
Track record
53 reports on REGN
11 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 17 of 21 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
- Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
- Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers